New mRNA vaccine targets RSV in first human trial

NCT ID NCT06573281

Completed ⭐️ VACCINE ⭐️ Sponsor: GlaxoSmithKline Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jul 31, 2026 · Updated 3 times

Summary

This early-stage trial is testing several doses of an experimental mRNA vaccine against RSV in 213 healthy adults aged 18-45. The goal is to check the vaccine's safety and how well it triggers an immune response. Participants receive two shots, and researchers monitor for side effects and measure antibody levels.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: mRNA-based RSV vaccine
What this could lead to: If successful, this could lead to a new vaccine to protect against RSV, a common respiratory virus that can be serious for infants and older adults.
What could go wrong: This is an early Phase 1 trial with only 213 healthy adults, so safety and immune response are still being tested. It may not work in larger, more diverse populations or against different RSV strains.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RESPIRATORY SYNCYTIAL VIRUS INFECTIONS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

respiratory syncytial virus infectious disease prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

RESPIRATORY SYNCYTIAL VIRUS INFECTIONS

Contacts and locations

Locations

GSK Investigational Site

Rolling Hills Estates, California, 90274, United States
GSK Investigational Site

Atlanta, Georgia, 30281, United States
GSK Investigational Site

Lenexa, Kansas, 66219, United States
GSK Investigational Site

Omaha, Nebraska, 68134, United States
GSK Investigational Site

Rochester, New York, 14609, United States
GSK Investigational Site

Camberwell, Victoria, 3124, Australia
GSK Investigational Site

Madrid, 28006, Spain
GSK Investigational Site

Madrid, 28046, Spain
GSK Investigational Site

Madrid, 28222, Spain

More trials for these conditions

Other studies related to the condition(s) this trial covers.